List of Excipients in API edaravone
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing edaravone
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Mitsubishi Tanabe Pharma America Inc | RADICAVA | edaravone | 70510-2171 | CYSTEINE HYDROCHLORIDE | |
| Mitsubishi Tanabe Pharma America Inc | RADICAVA | edaravone | 70510-2171 | PHOSPHORIC ACID | |
| Mitsubishi Tanabe Pharma America Inc | RADICAVA | edaravone | 70510-2171 | SODIUM BISULFITE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing edaravone
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Piramal Critical Care Inc | edaravone | 66794-259 | CYSTEINE HYDROCHLORIDE |
| Piramal Critical Care Inc | edaravone | 66794-259 | PHOSPHORIC ACID |
| Piramal Critical Care Inc | edaravone | 66794-259 | SODIUM BISULFITE |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for edaravone
Excipient focus: CYSTEINE HYDROCHLORIDE
edaravone drug variants containing CYSTEINE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Piramal Critical Care Inc | edaravone | 66794-259 |
| Gland Pharma Limited | edaravone | 68083-500 |
| Mitsubishi Tanabe Pharma America Inc | edaravone | 70510-2171 |
| >Company | >Ingredient | >NDC |
edaravone drug variants not containing CYSTEINE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PHOSPHORIC ACID
edaravone drug variants containing PHOSPHORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Piramal Critical Care Inc | edaravone | 66794-259 |
| Gland Pharma Limited | edaravone | 68083-500 |
| Mitsubishi Tanabe Pharma America Inc | edaravone | 70510-2171 |
| >Company | >Ingredient | >NDC |
edaravone drug variants not containing PHOSPHORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM BISULFITE
edaravone drug variants containing SODIUM BISULFITE
| Company | Ingredient | NDC |
|---|---|---|
| Piramal Critical Care Inc | edaravone | 66794-259 |
| Gland Pharma Limited | edaravone | 68083-500 |
| Mitsubishi Tanabe Pharma America Inc | edaravone | 70510-2171 |
| >Company | >Ingredient | >NDC |
edaravone drug variants not containing SODIUM BISULFITE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CHLORIDE
edaravone drug variants containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Piramal Critical Care Inc | edaravone | 66794-259 |
| Gland Pharma Limited | edaravone | 68083-500 |
| Mitsubishi Tanabe Pharma America Inc | edaravone | 70510-2171 |
| >Company | >Ingredient | >NDC |
edaravone drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
edaravone drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Piramal Critical Care Inc | edaravone | 66794-259 |
| Gland Pharma Limited | edaravone | 68083-500 |
| Mitsubishi Tanabe Pharma America Inc | edaravone | 70510-2171 |
| >Company | >Ingredient | >NDC |
edaravone drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
edaravone drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Piramal Critical Care Inc | edaravone | 66794-259 |
| Gland Pharma Limited | edaravone | 68083-500 |
| Mitsubishi Tanabe Pharma America Inc | edaravone | 70510-2171 |
| >Company | >Ingredient | >NDC |
edaravone drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
